We are live on ! Find out more
CLLS

Cellectis

70 hedge funds and large institutions have $210M invested in Cellectis in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

11% more funds holding

Funds holding: 6370 (+7)

1.4% more ownership

Funds ownership: 30.26%31.65% (+1.4%)

10% more call options, than puts

Call options by funds: $905K | Put options by funds: $823K

0% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 23

10% less capital invested

Capital invested by funds: $234M → $210M (-$24.1M)

Holders
70
Holders Change
+7
Holders Change %
+11.11%
% of All Funds
1.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
23
Reduced
23
Closed
6
Calls
$905K
Puts
$823K
Net Calls
+$82K
Net Calls Change
-$345K

CLLS Hedge Fund Activity: Q2 2019 in Review

70 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q2 2019, worth a combined $210M — down 10% from $234M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CLLS positions and 6 closed out — a net gain of 7 holders — while 23 added to existing stakes and 23 trimmed.

The largest buyer was Capital International Investors, opening a new position worth an estimated $7.51M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $8.22M sold.

  • 70 institutional investors held Cellectis (CLLS) as of Q2 2019, up from 63 in Q1 2019.
  • Funds reported $210M of Cellectis stock for Q2 2019, down 10% quarter-over-quarter.
  • 13 funds opened new Cellectis positions in Q2 2019 and 6 closed out, a net change of +7 holders.
  • The largest Cellectis buyer in Q2 2019 was Capital International Investors, an estimated $7.51M added.
  • The largest Cellectis seller in Q2 2019 was Sphera Funds Management, an estimated $8.22M sold.

Based on aggregated 13F filings for Q2 2019.